Biodexa Pharmaceuticals announces a one-for-ten reverse ADR split effective July 31, 2025, changing the ratio of ADRs.
Quiver AI Summary
Biodexa Pharmaceuticals PLC announced that a change in its American Depositary Receipts (ADR) ratio became effective on July 31, 2025, transitioning from one ADR representing 10,000 ordinary shares to one ADR representing 100,000 ordinary shares. This change equates to a one-for-ten reverse ADR split, which occurred automatically, with the previously-held ADRs being canceled and new ones issued by JPMorgan Chase Bank, the depositary bank. The company's total number of ordinary shares remains unaffected by this adjustment. Post-ratio change, there are 619,523 ADRs outstanding. The announcement includes forward-looking statements regarding the company's performance, emphasizing the potential risks and uncertainties that may impact actual results.
Potential Positives
- The company has successfully implemented a ratio change of its American Depositary Receipts (ADRs), which may streamline the trading and perception of its shares in the market.
- The ratio change is positioned as a reverse ADR split, potentially making the company's shares appear more valuable on a per-ADR basis, which could attract more investors.
- The company continues to emphasize its focus on innovative products for diseases with unmet medical needs, reinforcing its commitment to addressing important health challenges.
Potential Negatives
- The Ratio Change may be perceived negatively by investors as a form of reverse split, potentially signaling financial distress or a need to increase the stock price per share.
- The automatic cancellation of previously-held ADRs could create confusion among current ADR holders, affecting investor sentiment and trust in the company.
- The mention of forward-looking statements raises concerns about the uncertainty of the company's future performance, which may deter potential investors.
FAQ
What is the recent ADR Ratio Change for Biodexa Pharmaceuticals?
The ADR Ratio Change is from 1 ADR representing 10,000 shares to 1 ADR representing 100,000 shares, effective July 31, 2025.
How does this ADR Ratio Change affect shareholders?
The Ratio Change operates like a one-for-ten reverse ADR split, automatically exchanging new ADRs for previously-held ones.
How many ADRs will be outstanding after the Ratio Change?
Immediately following the Ratio Change, there were 619,523 ADRs outstanding.
Will the total number of ordinary shares change due to the ADR Ratio Change?
No, the total number of issued ordinary shares will remain 61,952,308,922 after the ADR Ratio Change.
What are forward-looking statements in Biodexa's announcement?
Forward-looking statements are predictions based on current data and management assumptions that involve risks and uncertainties affecting future performance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
July 31, 2025
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
ADR Ratio Change Effective
ADSs Outstanding Post Ratio Change
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces the previously announced ratio change of its American Depositary Receipts (“ADR”) from one (1) ADR representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000) ordinary shares (the "Ratio Change"), became effective at the open of business on July 31, 2025 (U.S. Eastern Time).
For ADR holders, the Ratio Change will have the same effect as a one-for-ten reverse ADR split. The exchange of one new ADR for every ten previously-held ADRs occurred automatically upon effectiveness, with the previously-held ADRs cancelled and the new ADRs issued by JPMorgan Chase Bank, N.A., the depositary bank for the Company’s ADR program.
Total Voting Rights
The number of issued ordinary shares of Biodexa will not be affected by this change. As of the date of this release, the number of issued ordinary shares of the Company is 61,952,308,922. Immediately following the Ratio Change, there were 619,523 ADRs outstanding.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
